MediciNova, Inc., and the JASDAQ Market of the Tokyo Stock Exchange announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.
Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034.
The allowed claims cover a method of reducing a triglyceride blood level, a method of reducing a total cholesterol blood level, and a method of reducing a low density lipoprotein (LDL) blood level using MN-001 or MN-002. The allowed claims cover oral administration including liquid and solid dosage forms.
